Coave Therapeutics – a company advancing the future of genetic medicines – announced the raising of €32 million ($33 million) in Series A funding. The funding was co-led by Novo Holdings A/S and Bpifrance, with Invus and UI Investissement participation alongside existing investors Seroba Life Sciences, Fund+, Kurma Partners, Omnes Capital, and Turenne Capital.
This funding will enable Coave to advance its proprietary ALIGATER (Advanced Vectors-Ligand Conjugates) platform, a technology addressing key limitations in delivering genetic payloads to extra-hepatic tissues, including limited tissue specificity, delivery efficiency and safety. ALIGATER enables the conjugation of targeting ligands, such as small molecules, peptides, or antibody fragments, on AAV or non-viral vectors, providing delivery efficiency, tissue specificity, and safety profile for a broad range of diseases. Plus, the platform streamlines the manufacturing process by avoiding prior AAV capsid modifications. These capabilities enable Coave to develop best-in-class gene therapies designed for specific indications.
This funding round will also enable Coave to advance its lead preclinical assets towards clinical development, primarily focusing on the central nervous system (CNS), as well as neuromuscular and eye diseases. And Coave plans to move two development candidates to CTA/IND-enabling studies in 2026.
Emmanuelle Coutanceau from Novo Holdings and Jean Francois Morin from Bpifrance will join Coave’s Board of Directors in connection with the funding.
KEY QUOTES:
“We are delighted to welcome this group of top-tier investors who share our vision for the ALIGATER platform. This funding is a critical milestone for Coave as we work to develop a new generation of targeted, safer, and more efficacious gene therapies. It also reinforces our ability to expand collaborations with pharma and biotech partners, driving innovation in the field of genetic medicines for a broad range of diseases.”
– Rodolphe Clerval, CEO of Coave
“Coave’s unique technology platform, strong proof-of-concept data, and experienced team, positions it as a leader in developing new generations of gene therapies. We are excited to see Coave acquiring one of our stealth-mode companies, broadening their international presence in Denmark.”
– Emmanuelle Coutanceau, Partner at Seed Investments, Novo Holdings
“Coave, with its ALIGATER platform for creating a new class of targeted gene therapies, has the potential to deliver groundbreaking new treatments to patients in need. With this Series A financing and a top tier team, Coave will be able to progress its pipeline of internal programs.”
– Jean-François Morin, Investment Director at Bpifrance – InnoBio Funds
